Empagliflozin/linagliptin, sold under the brand name Glyxambi, is a fixed-dose combination anti-diabetic medication used to treat type 2 diabetes.[4] It is a combination of empagliflozin and linagliptin.[4] It is taken by mouth.[4]
The most common side effects include urinary infections, nasopharyngitis, and upper respiratory tract infections .[4]
It was approved for use in the United States in January 2015,[5][6] for use in the European Union in November 2016,[7] and for use in Australia in December 2016.[8]
Medical uses
In the United States empagliflozin/linagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus and to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease.[4]
In the European Union empagliflozin/linagliptin is indicated in adults aged 18 years and older with type 2 diabetes mellitus:[7]
Adverse effects
The most common side effects include urinary infections, nasopharyngitis, and upper respiratory tract infections .[4][7] The most serious side effects include ketoacidosis (high blood levels of acids called ‘ketoacids’), pancreatitis (inflammation of the pancreas), hypersensitivity (allergic reactions) and hypoglycaemia (low blood sugar levels).[7]
History
The combination preparation was developed and is marketed by Boehringer Ingelheim and Eli Lilly and Company under the brand name Glyxambi.[9]
Further reading
References
- Empagliflozin / linagliptin (Glyxambi) Use During Pregnancy Drugs.com, 29 November 2018, retrieved 10 February 2020^
- Glyxambi 10 mg/5 mg Film-coated Tablets - Summary of Product Characteristics (SmPC) (emc), 18 December 2019, retrieved 10 February 2020^
- Glyxambi 25 mg/5 mg Film-coated Tablets - Summary of Product Characteristics (SmPC)